# Study of ABT-751 in Patients With Refractory Hematologic Malignancies

> **NCT00047489** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** ABT-751

## Key facts

- **NCT ID:** NCT00047489
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2005-01
- **Final completion:** 2005-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00047489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00047489, "Study of ABT-751 in Patients With Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00047489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*